Merck keeps it in the family as Robert Davis hands the CFO keys to Caroline Litchfield; Gilead loses Diana Brainard, with virology exec becoming CEO of AlloVir
→ With Robert Davis preparing to take over as Merck’s CEO, the Big Pharma stayed in-house to choose a successor in the job he won’t hold for much longer. Caroline Litchfield, who’s served at Merck since 1990 and has been treasurer the past two years, will become CFO on April 1, the same day Davis assumes the role of president. Davis will then take the helm for Ken Frazier on July 1.
In the four years before her tenure as treasurer, Litchfield led finance for the Human Health division, where Frank Clyburn just became president after Mike Nally’s departure last week as chief marketing officer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
